PPLPHARMA Q3 FY26 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹2,140 Cr
verified against source
Revenue YoY
—
reported change
EBITDA
Pending
latest reported figure
Source
screener in enriched
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Piramal Pharma's Q3 FY26 reflects a muted year as guided, with 9-month revenue of Rs 2,140 crore declining 3-4% YoY. The CDMO segment faced headwinds from inventory destocking at a key customer account and slower early-stage order inflows amid muted US biotech funding. However, early signs of recovery are emerging with a significant increase in RFPs and order pick-up since October 2025, supported by rebounding biopharma funding and increased M&A activity. The complex hospital generics (CHG) segment demonstrates resilient leadership, with inhalation anesthesia US market share expanding to 47% from 44%. Consumer healthcare continues its strong run with 20% YoY growth in Q3 and e-commerce now contributing 26% of PCH sales. The recently announced Kenalog acquisition from Bristol Myers Squibb ($35M upfront + $65M contingent) for expected annualized revenues of $30-40M complements the CHD portfolio. Management reaffirms FY26 guidance as a stretch target while the $2B revenue by 2030 aspiration remains intact. Key risks include sustained recovery depending on customer decision timelines and RO market pricing pressures for sevoflurane.
Colored figures show movement against the previous available record.
Guidance to track
- Management continues to stand by FY26 guidance despite acknowledging the target requires catch-up in remaining quarters; detailed FY27 guidance to be provided at subsequent board meeting.
- Long-term roadmap targeting $2B revenue by 2030 remains intact with CDMO expected to contribute ~$1B over next 3-4 years, supported by $90M capacity expansion.
- Average annual capex guidance of $70-100M, currently elevated near-term due to Lexington and Riverview expansions, with asset turns expected to reach 2-2.5x at optimum utilization.
- Long-term ETR expected in 24-25% range as overseas facilities reach optimum capacity utilization; tax losses available for carry-forward to offset accounting impact.
Risks flagged
- One major customer's inventory destocking continues to impact CDMO revenues with no specific resumption timeline provided. Management declined to quantify impact or reversal timeline for FY27.
- ROW sevoflurane approvals from Digwal taking longer than anticipated (now 12-18 months timeline). Management adopted cautious pricing strategy to avoid margin dilution, resulting in slower-than-expected ramp-up.
- $65M contingent consideration structure details not disclosed. Management deflected question on specific triggers and geographic sales breakdown, creating opacity around deal economics.
- Increased competition from Chinese suppliers in rest-of-world markets creating pricing pressure. Management chose not to be overly aggressive on price to protect margins, trading off revenue growth.
Key quotes
- We are seeing early signs of recovery with pick up in RFPs and order inflows on the back of improved biopharma funding and increased M&A activities in the US healthcare space.
- The overseas sites are inherently structured with high gross margin and so incremental revenue is highly beneficial to the financial metrics... asset turns currently are below one for our overseas facilities and eventually we do expect it to go to between two to two and a half at scale.
- We are not changing the guidance at the moment. We recognize that it is a stretch but I think we're going to endeavor to meet it.
Research modules